Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
This study is observing people in the UK who are taking Dupixent for their eczema (atopic dermatitis) in a real-world setting. Researchers want to learn more about who takes Dupixent, their medical history, and how severe their eczema is. They also want to understand how Dupixent is actually used, including typical doses, how long people stay on it, and why they might stop or switch. The study will look at how well Dupixent works in the long term, any other health conditions people have, and how Dupixent affects these. Safety information will also be collected. The aim is to get a clearer picture of Dupixent's effectiveness and safety outside of strict clinical trial conditions.
Auf einen Blick
Worum geht es in dieser Studie?
This study is all about understanding how a medicine called Dupixent, used for a type of eczema called atopic dermatitis, works for people in their daily lives. Instead of a highly controlled experiment, researchers are simply observing patients who are already taking Dupixent as part of their regular treatment. They want to learn more about the kinds of people who use Dupixent – their age, background, and how severe their eczema is before they start the medication.
Researchers are also keen to see how Dupixent is actually used in the real world. This includes things like the typical doses people take, how long they use it, and if they stop or switch to another treatment – and why. They'll also be looking at how well Dupixent helps people manage their eczema over a long period, which is really important for understanding its true benefits. They'll also check if Dupixent helps with other related conditions, like asthma or hay fever, that often occur alongside eczema.
Finally, a major part of the study is to collect information about any side effects people experience while taking Dupixent. This helps doctors and patients understand the safety of the medication even better. By gathering all this information over five years, the study aims to give a clearer, more complete picture of how Dupixent works for people with eczema in their everyday lives, beyond what we learn from initial trials.
Wichtige Erkenntnisse
- Researchers are observing how Dupixent works for people with eczema in their daily lives.
- The study aims to understand who takes Dupixent, how it's used, and how well it works long-term.
- It will also collect safety information and track other related health conditions.
- Participation involves providing information over five years, but doesn't change your medical care or provide free medication.
- You must be 12 or older and starting or recently started Dupixent for eczema to be considered.
- You can leave the study at any time without affecting your medical treatment.
Wer könnte berechtigt sein?
You might be able to take part in this study if you are 12 years old or older and are either about to start Dupixent for your eczema, or have recently started it (within the last 6 months).
If you're between 12 and 18, Dupixent must be approved for use in your age group in the UK for you to join. You'll also need to be able to understand and fill out some questionnaires and give your consent (or have your parent/guardian give it for you if you're under 18).
However, you won't be able to join if you have any health conditions that would make Dupixent unsuitable for you, if you have a very short expected lifespan, struggle with substance abuse, have severe memory problems, or other serious health issues that would make it hard to attend appointments. Also, if you're currently in another clinical trial that changes your medical care, or if you've recently used Dupixent in the last 6 months, you won't be eligible.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 12 Jahre alt oder älter?
- Are you starting or have you recently started (within the last 6 months) Dupixent for your eczema?
- Are you able to understand and complete questionnaires?
- Do you have any conditions that your doctor thinks might make it difficult for you to take part in a 5-year study?
- Are you currently taking part in another clinical trial that affects your medical care?
- Have you used Dupixent in the last 6 months (if you haven't just started it)?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you will be followed by the research team for five years. This involves regularly providing information about your health, your eczema, and how Dupixent is working for you. You'll likely complete questionnaires that ask about your symptoms, how your eczema affects your daily life, and any other health conditions you have. Since this is an observational study, you will continue to receive Dupixent as prescribed by your own doctor, and the study won't change your medical care. The goal is to simply observe your experiences. There are no special medications provided by the study, only data collection about your standard treatment. You will have regular assessments, similar to what your doctor might already do, to track your eczema and overall health during this five-year period.
Potenzielle Risiken und Vorteile
Locations (114)
- Investigational Site Number : 0320013Verifizierte PostleitzahlPilar, Argentinien
- Investigational Site Number : 0320012Verifizierte PostleitzahlRosario, Argentinien
- Investigational Site Number : 0320011Nur StadtCiudad Autonoma Bs As, Argentina
- Investigational Site Number : 0360002Verifizierte PostleitzahlKogarah, Australia
- Investigational Site Number : 0360005Verifizierte PostleitzahlKogarah, Australia
- Investigational Site Number : 0360003Verifizierte PostleitzahlWoolloongabba, Australia
- Investigational Site Number : 0360004Verifizierte PostleitzahlBedford Park, Australia
- Investigational Site Number : 0360001Verifizierte PostleitzahlCarlton, Australia
- Investigational Site Number : 0400005Verifizierte PostleitzahlGraz, Österreich
- Investigational Site Number : 0400004Verifizierte PostleitzahlLinz, Österreich
- Investigational Site Number : 0400002Verifizierte PostleitzahlMaria Enzersdorf, Austria
- Investigational Site Number : 0400001Verifizierte PostleitzahlWien, Österreich
Häufige Fragen
What is Dupixent?
Dupixent is a medicine used to treat moderate to severe eczema (atopic dermatitis) in adults and children.
Will I get free medicine if I join the study?
No, this study observes how Dupixent is used in real life. You will receive your medication as prescribed by your own doctor, not through the study.
Wie lange werde ich an der Studie teilnehmen?
If you join, you will be followed for five years to see how Dupixent affects your eczema over time.
Kann ich die Studie verlassen, wenn ich meine Meinung ändere?
Ja, Sie können die Studie jederzeit ohne Angabe von Gründen verlassen, und es wird sich nicht auf Ihre medizinische Versorgung auswirken.
What does 'real-world setting' mean?
It means the study looks at how Dupixent works for people in their everyday lives, not in strict, controlled trial conditions.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.